Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Skeletal muscle in MuRF1 null mice is not spared in low-gravity conditions, indicating atrophy proceeds by unique mechanisms in space.

Cadena SM, Zhang Y, Fang J, Brachat S, Kuss P, Giorgetti E, Stodieck LS, Kneissel M, Glass DJ.

Sci Rep. 2019 Jun 28;9(1):9397. doi: 10.1038/s41598-019-45821-9.

2.

Systemic sclerostin antibody treatment increases osseointegration and biomechanical competence of zoledronic-acid-coated dental implants in a rat osteoporosis model.

Korn P, Kramer I, Schlottig F, Tödtman N, Eckelt U, Bürki A, Ferguson SJ, Kautz A, Schnabelrauch M, Range U, Kneissel M, Stadlinger B.

Eur Cell Mater. 2019 May 17;37:333-346. doi: 10.22203/eCM.v037a20.

3.

Dkk1 KO Mice Treated with Sclerostin Antibody Have Additional Increases in Bone Volume.

Morse A, Cheng TL, Schindeler A, McDonald MM, Mohanty ST, Kneissel M, Kramer I, Little DG.

Calcif Tissue Int. 2018 Sep;103(3):298-310. doi: 10.1007/s00223-018-0420-6. Epub 2018 May 29.

PMID:
29845410
4.

Sost deficiency leads to reduced mechanical strains at the tibia midshaft in strain-matched in vivo loading experiments in mice.

Albiol L, Cilla M, Pflanz D, Kramer I, Kneissel M, Duda GN, Willie BM, Checa S.

J R Soc Interface. 2018 Apr;15(141). pii: 20180012. doi: 10.1098/rsif.2018.0012.

5.

Tough Composite Hydrogels with High Loading and Local Release of Biological Drugs.

Li J, Weber E, Guth-Gundel S, Schuleit M, Kuttler A, Halleux C, Accart N, Doelemeyer A, Basler A, Tigani B, Wuersch K, Fornaro M, Kneissel M, Stafford A, Freedman BR, Mooney DJ.

Adv Healthc Mater. 2018 May;7(9):e1701393. doi: 10.1002/adhm.201701393. Epub 2018 Feb 14.

6.

Sclerostin deficiency modifies the development of CKD-MBD in mice.

Kaesler N, Verhulst A, De Maré A, Deck A, Behets GJ, Hyusein A, Evenepoel P, Floege J, Marx N, Babler A, Kramer I, Kneissel M, Kramann R, Weis D, D'Haese PC, Brandenburg VM.

Bone. 2018 Feb;107:115-123. doi: 10.1016/j.bone.2017.11.015. Epub 2017 Nov 21.

PMID:
29175269
7.

Sclerostin Antibody Augments the Anabolic Bone Formation Response in a Mouse Model of Mechanical Tibial Loading.

Morse A, Schindeler A, McDonald MM, Kneissel M, Kramer I, Little DG.

J Bone Miner Res. 2018 Mar;33(3):486-498. doi: 10.1002/jbmr.3330. Epub 2017 Nov 29.

8.

Loading-Induced Reduction in Sclerostin as a Mechanism of Subchondral Bone Plate Sclerosis in Mouse Knee Joints During Late-Stage Osteoarthritis.

Jia H, Ma X, Wei Y, Tong W, Tower RJ, Chandra A, Wang L, Sun Z, Yang Z, Badar F, Zhang K, Tseng WJ, Kramer I, Kneissel M, Xia Y, Liu XS, Wang JHC, Han L, Enomoto-Iwamoto M, Qin L.

Arthritis Rheumatol. 2018 Feb;70(2):230-241. doi: 10.1002/art.40351. Epub 2017 Dec 29.

9.

Sost deficiency led to a greater cortical bone formation response to mechanical loading and altered gene expression.

Pflanz D, Birkhold AI, Albiol L, Thiele T, Julien C, Seliger A, Thomson E, Kramer I, Kneissel M, Duda GN, Kornak U, Checa S, Willie BM.

Sci Rep. 2017 Aug 25;7(1):9435. doi: 10.1038/s41598-017-09653-9.

10.

Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.

McDonald MM, Reagan MR, Youlten SE, Mohanty ST, Seckinger A, Terry RL, Pettitt JA, Simic MK, Cheng TL, Morse A, Le LMT, Abi-Hanna D, Kramer I, Falank C, Fairfield H, Ghobrial IM, Baldock PA, Little DG, Kneissel M, Vanderkerken K, Bassett JHD, Williams GR, Oyajobi BO, Hose D, Phan TG, Croucher PI.

Blood. 2017 Jun 29;129(26):3452-3464. doi: 10.1182/blood-2017-03-773341. Epub 2017 May 17.

11.

Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta.

Little DG, Peacock L, Mikulec K, Kneissel M, Kramer I, Cheng TL, Schindeler A, Munns C.

Bone. 2017 Aug;101:96-103. doi: 10.1016/j.bone.2017.04.016. Epub 2017 Apr 29.

PMID:
28461254
12.

The skeletal cell-derived molecule sclerostin drives bone marrow adipogenesis.

Fairfield H, Falank C, Harris E, Demambro V, McDonald M, Pettitt JA, Mohanty ST, Croucher P, Kramer I, Kneissel M, Rosen CJ, Reagan MR.

J Cell Physiol. 2018 Feb;233(2):1156-1167. doi: 10.1002/jcp.25976. Epub 2017 Jun 6.

13.

Suppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms.

Chandra A, Lin T, Young T, Tong W, Ma X, Tseng WJ, Kramer I, Kneissel M, Levine MA, Zhang Y, Cengel K, Liu XS, Qin L.

J Bone Miner Res. 2017 Feb;32(2):360-372. doi: 10.1002/jbmr.2996. Epub 2016 Oct 20.

14.

Only minor differences in renal osteodystrophy features between wild-type and sclerostin knockout mice with chronic kidney disease.

Cejka D, Parada-Rodriguez D, Pichler S, Marculescu R, Kramer I, Kneissel M, Gross T, Reisinger A, Pahr D, Monier-Faugere MC, Haas M, Malluche HH.

Kidney Int. 2016 Oct;90(4):828-34. doi: 10.1016/j.kint.2016.06.019. Epub 2016 Aug 12.

15.

Meckel's and condylar cartilages anomalies in achondroplasia result in defective development and growth of the mandible.

Biosse Duplan M, Komla-Ebri D, Heuzé Y, Estibals V, Gaudas E, Kaci N, Benoist-Lasselin C, Zerah M, Kramer I, Kneissel M, Porta DG, Di Rocco F, Legeai-Mallet L.

Hum Mol Genet. 2016 Jul 15;25(14):2997-3010. Epub 2016 Jun 3.

16.

Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction.

Wehmeyer C, Frank S, Beckmann D, Böttcher M, Cromme C, König U, Fennen M, Held A, Paruzel P, Hartmann C, Stratis A, Korb-Pap A, Kamradt T, Kramer I, van den Berg W, Kneissel M, Pap T, Dankbar B.

Sci Transl Med. 2016 Mar 16;8(330):330ra35. doi: 10.1126/scitranslmed.aac4351. Epub 2016 Mar 16.

PMID:
27089204
17.

Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model.

Komla-Ebri D, Dambroise E, Kramer I, Benoist-Lasselin C, Kaci N, Le Gall C, Martin L, Busca P, Barbault F, Graus-Porta D, Munnich A, Kneissel M, Di Rocco F, Biosse-Duplan M, Legeai-Mallet L.

J Clin Invest. 2016 May 2;126(5):1871-84. doi: 10.1172/JCI83926. Epub 2016 Apr 11.

18.

Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progression.

Haynes KR, Tseng HW, Kneissel M, Glant TT, Brown MA, Thomas GP.

BMC Musculoskelet Disord. 2015 Nov 26;16:368. doi: 10.1186/s12891-015-0823-8.

19.

Introduction special issue.

Kneissel M, Glass D.

Bone. 2015 Nov;80:1. doi: 10.1016/j.bone.2015.06.015. Epub 2015 Jun 23. No abstract available.

PMID:
26115912
20.

Endochondral fracture healing with external fixation in the Sost knockout mouse results in earlier fibrocartilage callus removal and increased bone volume fraction and strength.

Morse A, Yu NY, Peacock L, Mikulec K, Kramer I, Kneissel M, McDonald MM, Little DG.

Bone. 2015 Feb;71:155-63. doi: 10.1016/j.bone.2014.10.018. Epub 2014 Oct 30.

PMID:
25445453
21.

Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy.

Moe SM, Chen NX, Newman CL, Organ JM, Kneissel M, Kramer I, Gattone VH 2nd, Allen MR.

J Bone Miner Res. 2015 Mar;30(3):499-509. doi: 10.1002/jbmr.2372.

22.

Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels.

Chang MK, Kramer I, Huber T, Kinzel B, Guth-Gundel S, Leupin O, Kneissel M.

Proc Natl Acad Sci U S A. 2014 Dec 2;111(48):E5187-95. doi: 10.1073/pnas.1413828111. Epub 2014 Nov 17.

23.

Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta.

Roschger A, Roschger P, Keplingter P, Klaushofer K, Abdullah S, Kneissel M, Rauch F.

Bone. 2014 Sep;66:182-8. doi: 10.1016/j.bone.2014.06.015. Epub 2014 Jun 19.

PMID:
24953712
24.

Mechanical load increases in bone formation via a sclerostin-independent pathway.

Morse A, McDonald MM, Kelly NH, Melville KM, Schindeler A, Kramer I, Kneissel M, van der Meulen MC, Little DG.

J Bone Miner Res. 2014 Nov;29(11):2456-67. doi: 10.1002/jbmr.2278.

25.

AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women.

John MR, Harfst E, Loeffler J, Belleli R, Mason J, Bruin GJ, Seuwen K, Klickstein LB, Mindeholm L, Widler L, Kneissel M.

Bone. 2014 Jul;64:204-10. doi: 10.1016/j.bone.2014.04.015. Epub 2014 Apr 24.

PMID:
24769332
26.

Sclerostin deficiency is linked to altered bone composition.

Hassler N, Roschger A, Gamsjaeger S, Kramer I, Lueger S, van Lierop A, Roschger P, Klaushofer K, Paschalis EP, Kneissel M, Papapoulos S.

J Bone Miner Res. 2014 Oct;29(10):2144-51. doi: 10.1002/jbmr.2259.

27.

Dental and periodontal phenotype in sclerostin knockout mice.

Kuchler U, Schwarze UY, Dobsak T, Heimel P, Bosshardt DD, Kneissel M, Gruber R.

Int J Oral Sci. 2014 Jun;6(2):70-6. doi: 10.1038/ijos.2014.12. Epub 2014 Apr 4.

28.

Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.

Chang MK, Kramer I, Keller H, Gooi JH, Collett C, Jenkins D, Ettenberg SA, Cong F, Halleux C, Kneissel M.

J Bone Miner Res. 2014 Jan;29(1):29-42. doi: 10.1002/jbmr.2059.

29.

Osseointegration of biochemically modified implants in an osteoporosis rodent model.

Stadlinger B, Korn P, Tödtmann N, Eckelt U, Range U, Bürki A, Ferguson SJ, Kramer I, Kautz A, Schnabelrauch M, Kneissel M, Schlottig F.

Eur Cell Mater. 2013 Jul 8;25:326-40; discussion 339-40.

30.

Preface: the osteocyte.

Bonewald LF, Kneissel M, Johnson M.

Bone. 2013 Jun;54(2):181. doi: 10.1016/j.bone.2013.02.018. Epub 2013 Feb 26. No abstract available.

PMID:
23486185
31.

WNT signaling in bone homeostasis and disease: from human mutations to treatments.

Baron R, Kneissel M.

Nat Med. 2013 Feb;19(2):179-92. doi: 10.1038/nm.3074. Epub 2013 Feb 6. Review.

PMID:
23389618
32.

Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets.

Wöhrle S, Henninger C, Bonny O, Thuery A, Beluch N, Hynes NE, Guagnano V, Sellers WR, Hofmann F, Kneissel M, Graus Porta D.

J Bone Miner Res. 2013 Apr;28(4):899-911. doi: 10.1002/jbmr.1810.

33.

Silencing of parathyroid hormone (PTH) receptor 1 in T cells blunts the bone anabolic activity of PTH.

Bedi B, Li JY, Tawfeek H, Baek KH, Adams J, Vangara SS, Chang MK, Kneissel M, Weitzmann MN, Pacifici R.

Proc Natl Acad Sci U S A. 2012 Mar 20;109(12):E725-33. doi: 10.1073/pnas.1120735109. Epub 2012 Mar 5.

34.

Mef2c deletion in osteocytes results in increased bone mass.

Kramer I, Baertschi S, Halleux C, Keller H, Kneissel M.

J Bone Miner Res. 2012 Feb;27(2):360-73. doi: 10.1002/jbmr.1492.

35.

Studying gene expression in bone by in situ hybridization.

Kramer I, Salie R, Susa M, Kneissel M.

Methods Mol Biol. 2012;816:305-20. doi: 10.1007/978-1-61779-415-5_20.

PMID:
22130937
36.

Isolation of mouse osteocytes using cell fractionation for gene expression analysis.

Halleux C, Kramer I, Allard C, Kneissel M.

Methods Mol Biol. 2012;816:55-66. doi: 10.1007/978-1-61779-415-5_5.

PMID:
22130922
37.

ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans.

John MR, Widler L, Gamse R, Buhl T, Seuwen K, Breitenstein W, Bruin GJ, Belleli R, Klickstein LB, Kneissel M.

Bone. 2011 Aug;49(2):233-41. doi: 10.1016/j.bone.2011.04.007. Epub 2011 Apr 14.

PMID:
21514409
38.

Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function.

Leupin O, Piters E, Halleux C, Hu S, Kramer I, Morvan F, Bouwmeester T, Schirle M, Bueno-Lozano M, Fuentes FJ, Itin PH, Boudin E, de Freitas F, Jennes K, Brannetti B, Charara N, Ebersbach H, Geisse S, Lu CX, Bauer A, Van Hul W, Kneissel M.

J Biol Chem. 2011 Jun 3;286(22):19489-500. doi: 10.1074/jbc.M110.190330. Epub 2011 Apr 6.

39.

Penta-substituted benzimidazoles as potent antagonists of the calcium-sensing receptor (CaSR-antagonists).

Gerspacher M, Altmann E, Beerli R, Buhl T, Endres R, Gamse R, Kameni-Tcheudji J, Kneissel M, Krawinkler KH, Missbach M, Schmidt A, Seuwen K, Weiler S, Widler L.

Bioorg Med Chem Lett. 2010 Sep 1;20(17):5161-4. doi: 10.1016/j.bmcl.2010.07.016. Epub 2010 Aug 3.

PMID:
20685119
40.

Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis.

Kramer I, Halleux C, Keller H, Pegurri M, Gooi JH, Weber PB, Feng JQ, Bonewald LF, Kneissel M.

Mol Cell Biol. 2010 Jun;30(12):3071-85. doi: 10.1128/MCB.01428-09. Epub 2010 Apr 19.

41.

1-Alkyl-4-phenyl-6-alkoxy-1H-quinazolin-2-ones: a novel series of potent calcium-sensing receptor antagonists.

Widler L, Altmann E, Beerli R, Breitenstein W, Bouhelal R, Buhl T, Gamse R, Gerspacher M, Halleux C, John MR, Lehmann H, Kalb O, Kneissel M, Missbach M, Müller IR, Reidemeister S, Renaud J, Taillardat A, Tommasi R, Weiler S, Wolf RM, Seuwen K.

J Med Chem. 2010 Mar 11;53(5):2250-63. doi: 10.1021/jm901811v.

PMID:
20158186
42.

Does osteocytic SOST suppression mediate PTH bone anabolism?

Kramer I, Keller H, Leupin O, Kneissel M.

Trends Endocrinol Metab. 2010 Apr;21(4):237-44. doi: 10.1016/j.tem.2009.12.002. Epub 2010 Jan 13. Review.

PMID:
20074973
43.

Ubiquitous overexpression of Hey1 transcription factor leads to osteopenia and chondrocyte hypertrophy in bone.

Salie R, Kneissel M, Vukevic M, Zamurovic N, Kramer I, Evans G, Gerwin N, Mueller M, Kinzel B, Susa M.

Bone. 2010 Mar;46(3):680-94. doi: 10.1016/j.bone.2009.10.022. Epub 2009 Oct 24.

PMID:
19857617
44.

Absence of estrogen receptor-related-alpha increases osteoblastic differentiation and cancellous bone mineral density.

Delhon I, Gutzwiller S, Morvan F, Rangwala S, Wyder L, Evans G, Studer A, Kneissel M, Fournier B.

Endocrinology. 2009 Oct;150(10):4463-72. doi: 10.1210/en.2009-0121. Epub 2009 Jul 16.

PMID:
19608650
45.

Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice.

Kramer I, Loots GG, Studer A, Keller H, Kneissel M.

J Bone Miner Res. 2010 Feb;25(2):178-89. doi: 10.1359/jbmr.090730.

46.

Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally.

Zhang Y, Kwon S, Yamaguchi T, Cubizolles F, Rousseaux S, Kneissel M, Cao C, Li N, Cheng HL, Chua K, Lombard D, Mizeracki A, Matthias G, Alt FW, Khochbin S, Matthias P.

Mol Cell Biol. 2008 Mar;28(5):1688-701. doi: 10.1128/MCB.01154-06. Epub 2008 Jan 7.

47.

Bone structure and metabolism in a rodent model of male senile osteoporosis.

Pietschmann P, Skalicky M, Kneissel M, Rauner M, Hofbauer G, Stupphann D, Viidik A.

Exp Gerontol. 2007 Nov;42(11):1099-108. Epub 2007 Oct 18.

PMID:
17949933
48.

Control of the SOST bone enhancer by PTH using MEF2 transcription factors.

Leupin O, Kramer I, Collette NM, Loots GG, Natt F, Kneissel M, Keller H.

J Bone Miner Res. 2007 Dec;22(12):1957-67.

49.

Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.

Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM.

Genome Res. 2005 Jul;15(7):928-35. Epub 2005 Jun 17.

50.

SOST is a target gene for PTH in bone.

Keller H, Kneissel M.

Bone. 2005 Aug;37(2):148-58.

PMID:
15946907

Supplemental Content

Loading ...
Support Center